Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen

Can Automation Increase Investment in Gene Therapies?

The potential of gene therapies will only be realized if the manufacturing challenges can be resolved, and that’s a tricky task. “Gene therapies can be transformative,” says Charles Gersbach, PhD, a biomedical engineer at Duke University. “They can treat diseases that are otherwise untreatable, but—like any new modality—the potential that gene therapy has is matched with its complexities, which leads to some challenges.” One of the key challenge…

Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen

Team prepares for commercialization bolstered by START Program and regulatory recognition